Researchers at the University of California, Davis, have adapted novel soluble epoxide hydrolase (sEHI) inhibitors as adjuvant treatment in cardiac cell-based therapy to improve the survival and engraftment of stem cells by pre-conditioning with the sEHI in vitro.
Cardiovascular disease is the leading cause of death for both men and women in the United States. Once cardiac failure has developed, the condition cannot be reversed. In current medical practice, only symptomatic treatment is available to ameliorate the symptoms. Existing cell-based cardiac therapies are being extensively investigated to potentially treat heart failure, as it could replace procedures like cardiac transplantation that are only available as definitive therapy.
Researchers at the University of California, Davis, have discovered that the survival and engraftment of stem cells (e.g. in cardiac tissue) can be increased by first exposing the stem cells to an inhibitor of soluble epoxide hydrolase in vitro. By using the novel soluble epoxide hydrolase (sEHI) inhibitors as adjuvant treatment in cell-based cardiac therapies, they successfully conditioned stem cells in vitro, which then resulted in significantly reduced oxidative stress causing lowered stem cell apoptosis. The survival of these stem cells is then improved when transplanted into the tissue of a subject. This method is also useful in treating cardiomyopathy or cardiac arrhythmia, as it can either reverse, mitigate, and/or improve the symptoms associated with these conditions.
|Patent Cooperation Treaty||Reference for National Filings||2018231702||12/20/2018||2017-958|
cardiac cell-based therapy, cardiac failure, drug therapy, heart, epoxide hydrolase-inhibitors, heart attack, stem cells, in vitro, cardiovascular disease